Immediate Release: Wednesday 12 November 2008
CLS Holdings PLC ("CLS") Announces a New Letting at
Maximilian Forum, Martinsried, Germany
CLS is pleased to announce a further letting of 1,200 sq m (12,917 sq ft) at
Maximilian Forum to MediGene AG, a biotech company who concentrates on
researching, developing, and commercialising novel drugs in two therapeutic
areas: cancer and autoimmune diseases.
The lease (1,200 sq m) is for a term of eight years with an option to prolong
for five years at the end of the fixed term. There is no break option. The
annual rent is €152,000 (£123,356) with annual indexation to German CPI.
MediGene AG now occupy (including this letting) a total area of 5,970 sq m
(64,583 sq ft) at Maximilian Forum which generates a total rent of €892,320 per
annum (£724,162 per annum).
Sten Mortstedt, Executive Chairman of CLS, commented:
"We are delighted that Medigene have the requirement for further space within
this property and we look forward to our continued relationship with them."
-ends-
For further information, please contact:
Sten Mortstedt, Executive Chairman
Henry Klotz, Chief Executive Officer
CLS Holdings plc
Tel: +44 20 7582 7766
www.clsholdings.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.